StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3092% above fair value
$58.51+0.52 (+0.90%)

Close on Nov 17, 2026Market cap $11.33BP/E 154.0Yield –

BioMarin Pharmaceutical r&d expenses

Research and development expenses are spending on new products and technology.

BioMarin Pharmaceutical's R&D Expenses for the twelve months ending Jun 30, 2026 was $987.64M, up 45.6% year over year. For fiscal 2025 it was $921.93M, up 23.4% from the year before. Over ten years it grew 3.8% a year on average. The highest annual figure on record is $921.93M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$921.93M+23.4%
FY2024Dec 31, 2024$747.18M+0.1%
FY2023Dec 31, 2023$746.77M+15.0%
FY2022Dec 31, 2022$649.61M+3.3%
FY2021Dec 31, 2021$628.79M+0.1%
FY2020Dec 31, 2020$628.12M-12.2%
FY2019Dec 31, 2019$715.01M+2.7%
FY2018Dec 31, 2018$696.33M+14.0%
FY2017Dec 31, 2017$610.75M-7.7%
FY2016Dec 31, 2016$661.91M+4.3%
FY2015Dec 31, 2015$634.81M+37.5%
FY2014Dec 31, 2014$461.54M+30.1%
FY2013Dec 31, 2013$354.78M+17.4%
FY2012Dec 31, 2012$302.22M+41.0%
FY2011Dec 31, 2011$214.37M+45.5%
FY2010Dec 31, 2010$147.31M+28.0%
FY2009Dec 31, 2009$115.12M+23.4%
FY2008Dec 31, 2008$93.29M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$206.95M+28.3%
Q1 FY2026Mar 31, 2026$178.80M+12.6%
Q4 FY2025Dec 31, 2025$192.41M+10.9%
Q3 FY2025Sep 30, 2025$409.48M+121.5%
Q2 FY2025Jun 30, 2025$161.31M-12.2%
Q1 FY2025Mar 31, 2025$158.73M-22.6%
Q4 FY2024Dec 31, 2024$173.51M-15.9%
Q3 FY2024Sep 30, 2024$184.90M-3.4%
Q2 FY2024Jun 30, 2024$183.79M+3.6%
Q1 FY2024Mar 31, 2024$204.99M+19.3%
Q4 FY2023Dec 31, 2023$206.25M+19.4%
Q3 FY2023Sep 30, 2023$191.31M+21.2%
Q2 FY2023Jun 30, 2023$177.36M+12.1%
Q1 FY2023Mar 31, 2023$171.85M+6.8%
Q4 FY2022Dec 31, 2022$172.75M+7.2%
Q3 FY2022Sep 30, 2022$157.83M-0.0%
Q2 FY2022Jun 30, 2022$158.19M-1.8%
Q1 FY2022Mar 31, 2022$160.84M+8.1%
Q4 FY2021Dec 31, 2021$161.09M+2.8%
Q3 FY2021Sep 30, 2021$157.87M+7.4%
Q2 FY2021Jun 30, 2021$161.11M-11.5%
Q1 FY2021Mar 31, 2021$148.73M+4.5%
Q4 FY2020Dec 31, 2020$156.67M-9.3%
Q3 FY2020Sep 30, 2020$147.05M-15.0%
Q2 FY2020Jun 30, 2020$182.14M-1.9%
Q1 FY2020Mar 31, 2020$142.26M-22.5%
Q4 FY2019Dec 31, 2019$172.81M-1.5%
Q3 FY2019Sep 30, 2019$172.96M+7.2%
Q2 FY2019Jun 30, 2019$185.64M+5.7%
Q1 FY2019Mar 31, 2019$183.59M-0.2%
Q4 FY2018Dec 31, 2018$175.39M+4.0%
Q3 FY2018Sep 30, 2018$161.41M+4.7%
Q2 FY2018Jun 30, 2018$175.58M+22.8%
Q1 FY2018Mar 31, 2018$183.95M+26.9%
Q4 FY2017Dec 31, 2017$168.61M-3.8%
Q3 FY2017Sep 30, 2017$154.10M-4.2%
Q2 FY2017Jun 30, 2017$143.04M–
Q1 FY2017Mar 31, 2017$145.00M–
Q4 FY2016Dec 31, 2016$175.24M–
Q3 FY2016Sep 30, 2016$160.83M–

More BioMarin Pharmaceutical figures

See a number that looks wrong?